J&J’s Solid Launches Lead Strong Pharma Segment Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson’s pharma unit posted strong sales growth in immunology and infectious disease, while its burgeoning oncology business is growing substantially.